Should a borderline negative HER2 result in a core biopsy of invasive carcinoma of the breast have HER2 assessment repeated in the excision specimen?
暂无分享,去创建一个
E. Rakha | Z. Hodi | Andrew H. S. Lee | P. Wencyk | Areeg Abbas | I. Ellis
[1] I. Ellis,et al. UK recommendations for HER2 assessment in breast cancer: an update , 2022, Journal of Clinical Pathology.
[2] E. Provenzano,et al. Receptor Status after Neoadjuvant Therapy of Breast Cancer: Significance and Implications , 2022, Pathobiology.
[3] I. Ellis,et al. Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases , 2021, British Journal of Cancer.
[4] L. Norton,et al. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy , 2019, Breast Cancer Research and Treatment.
[5] John M S Bartlett,et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] John M S Bartlett,et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.
[7] John M S Bartlett,et al. Updated UK Recommendations for HER2 assessment in breast cancer , 2014, Journal of Clinical Pathology.
[8] John M S Bartlett,et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.
[9] I. Ellis,et al. Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast , 2012, Histopathology.
[10] M. Dowsett,et al. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] Rohit Bhargava,et al. Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases , 2008, Modern Pathology.
[12] I. Ellis,et al. HER2 testing in the UK: further update to recommendations , 2008, Journal of Clinical Pathology.
[13] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[14] D. Visscher,et al. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. , 2005, American journal of clinical pathology.
[15] T. Ivković-Kapicl,et al. [Human epidermal growth factor receptor 2 testing in breast cancer]. , 2010, Medicinski pregled.